CStone Pharmaceuticals, a biopharmaceutical company, researches, develops, and commercializes immuno-oncology and precision medicines to address the unmet medical needs of cancer patients in China and internationally. It offers Sugemalimab, a monoclonal antibody against programmed death (PD) ligand 1; GAVRETO, an RET inhibitor for the treatment of patients with advanced or metastatic RET-mutant medullary and RET fusion-positive thyroid cancers; and avapritinib, a KIT/PDGFRA inhibitor to treat adults with unresectable or metastatic gastrointestinal stromal tumors harboring a PDGFRA exon 18 mutation. The company's product pipeline includes Nofazinlimab, a PD-1 antibody for the treatment of patients with hepatocellular carcinoma; Ivosidenib, an isocitrate dehydrogenase 1 (IDH1) inhibitor to treat adults with relapsed or refractory acute myeloid leukemia with an IDH1 mutation; and Fisogatinib, an FGFR4 inhibitor to treat hepatocellular carcinoma. Its products also comprise CS1002, CS2006, CS3002, CS3005, CS2007, CS2008, and CS500 for solid tumors; and CS5001 for solid tumors and hematologic malignancies. The company was incorporated in 2015 and is headquartered in Shanghai, China.

CStone Pharmaceuticals

Xynomic Pharmaceuticals Holdings, Inc. is a clinical stage biopharmaceutical company focused on in-licensing, developing and commercializing oncology drug candidates in China, US, and the rest of the world.

Metric
Company Name	CStone Pharmaceuticals	Xynomic Pharmaceuticals Holdings, Inc.
Symbol	2.62K
MSH ID	COM:CSTONEPHARMA	COM:XYNOMICPHARMA
Market	STOCKS	PRIVATE
Sector	Healthcare	Healthcare & Health Services
Industry	Biotechnology	Pharmaceuticals
Country	CN	US
Stage		Series B
Employee Count	230
Website	cstonepharma.com	xynomicpharma.com
LinkedIn
Founders

Metric
Market Cap	201.63M
Enterprise Value
Monthly Web Traffic		1.52K
Web Traffic Growth		4.19
Valuation
Raised Capital

Metric
Revenue	63.80M
Revenue (LTM)
Revenue (NTM)
Gross Profit	41.85M
EBITDA	-65.53M
Operating Income	-73.53M
Net Income	-50.51M
EPS	-0.04
Diluted EPS	-0.04
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.71
Operating Profit Margin	-0.78
EBITDA Margin	-1.03
Net Profit Margin	-0.31
Return on Equity	-0.31
Return on Assets	-0.09
Return on Capital Employed	-0.43

2616

COM:CSTONEPHARMA

CStone Pharmaceuticals Co Ltd

Last Close

2.54

14/02 08:08

Market Cap

1.57B

Beta: -

Volume Today

6.09M

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-1.69
P/B Ratio	3.63
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	7.55
EV Multiple	-2.61

Metric
Days Sales Outstanding
Days Payables Outstanding	522.21
Days Inventory Outstanding	495.78
Operating Cycle	638.96
Cash Conversion Cycle	-30.27
Asset Turnover	0.30

Metric
Operating Cash Flow	-80.99M
Free Cash Flow	-89.94M
Cash Flow to Debt	-1.27
Operating Cash Flow/Sales	-0.95
Free Cash Flow Yield	-0.40

Metric
Cash & Equivalents	137.09M
Accounts Receivable
Inventory	14.97M
Goodwill
Debt to Capitalization	0.42
Debt to Assets	0.17
Current Ratio	1.32
Quick Ratio	1.51

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.30
R&D to Revenue	1.28
SG&A to Revenue	0.13